AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 157 filers reported holding AKERO THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.70 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $17,188 | +157.3% | 339,846 | +137.5% | 0.01% | +175.0% |
Q2 2023 | $6,680 | +126.1% | 143,078 | +85.3% | 0.00% | +300.0% |
Q1 2023 | $2,954 | -47.9% | 77,224 | -25.4% | 0.00% | -66.7% |
Q4 2022 | $5,674 | -85.8% | 103,552 | +8616.5% | 0.00% | – |
Q3 2022 | $40,000 | -64.9% | 1,188 | -90.2% | 0.00% | – |
Q2 2022 | $114,000 | +6.5% | 12,078 | +58.7% | 0.00% | – |
Q1 2022 | $107,000 | -92.9% | 7,610 | -89.3% | 0.00% | – |
Q4 2021 | $1,498,000 | +375.6% | 70,860 | +403.7% | 0.00% | – |
Q3 2021 | $315,000 | +131.6% | 14,068 | +156.9% | 0.00% | – |
Q2 2021 | $136,000 | -63.1% | 5,476 | -57.1% | 0.00% | – |
Q1 2021 | $369,000 | +141.2% | 12,757 | +114.8% | 0.00% | – |
Q4 2020 | $153,000 | -39.3% | 5,938 | -27.3% | 0.00% | – |
Q3 2020 | $252,000 | -41.9% | 8,169 | -53.0% | 0.00% | – |
Q2 2020 | $434,000 | +635.6% | 17,399 | +525.4% | 0.00% | – |
Q1 2020 | $59,000 | -47.3% | 2,782 | -44.6% | 0.00% | – |
Q4 2019 | $112,000 | +83.6% | 5,018 | +88.9% | 0.00% | – |
Q3 2019 | $61,000 | – | 2,657 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 5,830,203 | $179,512,000 | 24.20% |
venBio Partners LLC | 2,444,311 | $75,260,000 | 11.44% |
Versant Venture Management, LLC | 777,727 | $23,946,000 | 4.38% |
Redmile Group, LLC | 2,336,357 | $71,936,000 | 1.32% |
Vivo Capital, LLC | 571,833 | $17,607,000 | 1.02% |
Cormorant Asset Management, LP | 859,550 | $26,466,000 | 1.02% |
Boxer Capital, LLC | 831,495 | $25,602,000 | 0.88% |
Integral Health Asset Management, LLC | 85,000 | $2,617,000 | 0.80% |
EAM Global Investors LLC | 49,718 | $1,531,000 | 0.56% |
Crawford Lake Capital Management, LLC | 43,826 | $1,349,000 | 0.56% |